Search Results - "Clemens, Michael R"

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study by KAUFMAN, Bella, MACKEY, John R, REVIL, Cédric, JONES, Alison, CLEMENS, Michael R, BAPSY, Poonamalle P, VAID, Ashok, WARDLEY, Andrew, TJULANDIN, Sergei, JAHN, Michaela, LEHLE, Michaela, FEYEREISLOVA, Andrea

“…TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor…”
Get full text

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study by VON MINCKWITZ, Gunter, DU BOIS, Andreas, BAUMANN, Klaus H, CLEMENS, Michael R, DUERR, Ralph, ULEER, Christoph, ANDERSSON, Michael, STEIN, Robert C, NEKIJUDOVA, Valentina, LOIBL, Sibylle, SCHMIDT, Marcus, MAASS, Nicolai, CUFER, Tanja, DE JONGH, Felix E, MAARTENSE, Eduard, ZIELINSKI, Christoph, KAUFMANN, Manfred, BAUER, Wolfgang

“…Trastuzumab shows clinical activity in human epidermal growth factor receptor 2 (HER-2)-positive early and advanced breast cancer. In the German Breast Group…”
Get full text

Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104 by Kruger, Stephan, Boeck, Stefan, Heinemann, Volker, Laubender, Ruediger P, Vehling-Kaiser, Ursula, Waldschmidt, Dirk, Kettner, Erika, Märten, Angela, Winkelmann, Cornelia, Klein, Stefan, Kojouharoff, Georgi, Gauler, Thomas C, Fischer von Weikersthal, Ludwig, Clemens, Michael R, Geissler, Michael, Greten, Tim F, Hegewisch-Becker, Susanna, Modest, Dominik P, Stintzing, Sebastian, Haas, Michael

“…Drug-induced skin toxicity may correlate with treatment efficacy in cancer patients receiving chemotherapy or biological agents. The correlation of the…”
Get more information

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer by Clemens, Michael R., Gladkov, Oleg A., Gartner, Elaina, Vladimirov, Vladimir, Crown, John, Steinberg, Joyce, Jie, Fei, Keating, Anne

“…The objective of this study was to assess the efficacy and tolerability of YM155, a survivin suppressor, in combination with docetaxel, compared with docetaxel…”
Get full text

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104) by Heinemann, Volker, Vehling-Kaiser, Ursula, Waldschmidt, Dirk, Kettner, Erika, Märten, Angela, Winkelmann, Cornelia, Klein, Stefan, Kojouharoff, Georgi, Gauler, Thomas C, von Weikersthal, Ludwig Fischer, Clemens, Michael R, Geissler, Michael, Greten, Tim F, Hegewisch-Becker, Susanna, Rubanov, Oleg, Baake, Gerold, Höhler, Thomas, Ko, Yon D, Jung, Andreas, Neugebauer, Sascha, Boeck, Stefan

“…AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer (PC): a reference sequence of gemcitabine/erlotinib followed by 2nd-line…”
Get more information

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials by Ormanns, Steffen, Haas, Michael, Baechmann, Sibylle, Altendorf-Hofmann, Annelore, Remold, Anna, Quietzsch, Detlef, Clemens, Michael R, Bentz, Martin, Geissler, Michael, Lambertz, Helmut, Kruger, Stephan, Kirchner, Thomas, Heinemann, Volker, Boeck, Stefan

“…Background: Conflicting results on the role of secreted protein acidic and rich in cysteins (SPARC) expression have been reported in resected pancreatic ductal…”
Get full text

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer by Haas, Michael, Ormanns, Steffen, Baechmann, Sibylle, Remold, Anna, Kruger, Stephan, Westphalen, Christoph B, Siveke, Jens T, Wenzel, Patrick, Schlitter, Anna Melissa, Esposito, Irene, Quietzsch, Detlef, Clemens, Michael R, Kettner, Erika, Laubender, Ruediger P, Jung, Andreas, Kirchner, Thomas, Boeck, Stefan, Heinemann, Volker

“…Background: Mutations in the KRAS gene can be detected in about 70–90% of pancreatic cancer (PC) cases. Whether these mutations have a prognostic or predictive…”
Get full text

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40) by von Minckwitz, Gunter, Darb-Esfahani, Silvia, Loibl, Sibylle, Huober, Jens, Tesch, Hans, Solbach, Christine, Holms, Frank, Eidtmann, Holger, Dietrich, Klaus, Just, Marianne, Clemens, Michael R., Hanusch, Claus, Schrader, Iris, Henschen, Stephan, Hoffmann, Gerald, Tiemann, Katharina, Diebold, Kurt, Untch, Michael, Denkert, Carsten

“…Adjacent ductal carcinoma in situ (DCIS) is found in approximately 45% of invasive ductal carcinomas (IDC) of the breast. Pure DCIS overexpresses HER2 in…”
Get full text

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104 by Ormanns, Steffen, Siveke, Jens T, Heinemann, Volker, Haas, Michael, Sipos, Bence, Schlitter, Anna Melissa, Esposito, Irene, Jung, Andreas, Laubender, Rüdiger P, Kruger, Stephan, Vehling-Kaiser, Ursula, Winkelmann, Cornelia, Fischer von Weikersthal, Ludwig, Clemens, Michael R, Gauler, Thomas C, Märten, Angela, Geissler, Michael, Greten, Tim F, Kirchner, Thomas, Boeck, Stefan

“…The role of pERK, pAKT and p53 as biomarkers in patients with advanced pancreatic cancer has not yet been defined. Within the phase III study AIO-PK0104 281…”
Get full text

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ by Boeck, Stefan, Vehling-Kaiser, Ursula, Waldschmidt, Dirk, Kettner, Erika, Märten, Angela, Winkelmann, Cornelia, Klein, Stefan, Kojouharoff, Georgi, Gauler, Thomas, Fischer von Weikersthal, Ludwig, Clemens, Michael R, Geissler, Michael, Greten, Tim F, Hegewisch-Becker, Susanna, Neugebauer, Sascha, Heinemann, Volker

“…To date, only limited toxicity data are available for the combination of erlotinib with either capecitabine or gemcitabine as front-line therapy for advanced…”
Get full text

Impact of SPARC expression level on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: A pooled analysis from prospective clinical and translational trials by Ormanns, Steffen, Haas, Michael, Baechmann, Sibylle, Remold, Anna, Quietzsch, Detlef, Clemens, Michael R., Bentz, Martin, Schoppmeyer, Konrad, Kruger, Stephan, Kirchner, Thomas, Heinemann, Volker, Boeck, Stefan Hubert

“…Abstract only…”
Get full text

Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer by Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R., Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kummel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald, Kreipe, Hans Heinrich, Nitz, Ulrike

“…Abstract only 504 Background: Optimal chemotherapy in HER2-negative, particularly HR-positive, early breast cancer (EBC), especially the survival impact of…”
Get full text

Fish oil preparations rich in docosahexaenoic acid modify platelet responsiveness to prostaglandin-endoperoxide/thromboxane A2 receptor agonists by Scheurlen, M, Kirchner, M, Clemens, M R, Jaschonek, K

“…The effects of daily dietary supplementation for 6 weeks with either 4.5 g eicosapentaenoic acid (EPA) and 3.35 g docosahexaenoic acid (DHA) (group I, EPA/DHA…”
Get more information

Phase II randomized, open-label study of YM155 (sepantronium bromide) plus docetaxel versus docetaxel alone as first-line treatment for HER2 negative metastatic breast cancer by Clemens, Michael R., Keating, Anne Therese, Gladkov, Oleg, Jie, Fei, Steinberg, Joyce, Gartner, Elaina M., Crown, John, Vladimirov, Vladimir Ivanovich

“…Abstract only 548 Background: YM155 (YM) is a small molecule survivin suppressant. In a phase I/II study of YM plus docetaxel (D) in solid tumors evidence of…”
Get full text

Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial by Degenhardt, Tom, Kreipe, Hans Heinrich, Gluz, Oleg, Kates, Ronald E., Liedtke, Cornelia, Kraemer, Stefan, Clemens, Michael R., Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Stefek, Andrea, Heyl, Volker, Wuerstlein, Rachel, Nitz, Ulrike, Harbeck, Nadia, Christgen, Matthias

“…Abstract only…”
Get full text

A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69 by Jackisch, Christian, Wiebringhaus, Frank, Conrad, Bettina, Weigel, Michael, Aktas, Bahriye, Wagner, Harald, Latos, Kunibert, Kohls, Andreas, Bueckner, Ute, Hauzenberger, Tanja, Bangemann, Nikola, Hackmann, John, Clemens, Michael R., Heinrich, Bernhard, Tome, Oliver, Loibl, Sibylle, Nekljudova, Valentina, Von Minckwitz, Gunter

“…Abstract only TPS1141 Background: Anthracyclines (A) followed by taxanes (T) are standard of care for neoadjuvant therapy in breast cancer (BC). A reverse…”
Get full text

Persistence of HER2 overexpression on circulating tumor cells in patients after systemic treatment for HER2-positive breast cancer: Follow-up results of the German Success B trial by Neugebauer, Julia Katharina, Rack, Brigitte Kathrin, Jaeger, Bernadette Anna Sophia, Andergassen, Ulrich, Pestka, Aurelia, Fasching, Peter A., Friedl, Thomas W. P., Mouarrawy, Doraid, Clemens, Michael R., Ziemendorff, Gabriele, Heinrich, Georg, von Abel, Ekkehard, Schneeweiss, Andreas, Beckmann, Matthias W., Pantel, Klaus, Janni, Wolfgang

“…Abstract only 11043 Background: The discordance between HER2-expression on circulating tumor cells (CTC) in peripheral blood and the primary tumor has already…”
Get full text

Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104) by Boeck, Stefan Hubert, Ormanns, Steffen, Laubender, Ruediger Paul, Jung, Andreas, Siveke, Jens T, Haas, Michael, Neumann, Jens, Vehling-Kaiser, Ursula, Winkelmann, Cornelia, Fischer von Weikersthal, Ludwig, Clemens, Michael R., Gauler, Thomas C., Marten, Angela, Klein, Stefan, Kojouharoff, Georgi, Geissler, Michael, Greten, Tim F, Kirchner, Thomas, Heinemann, Volker

“…Abstract only 189 Background: Validated biomarkers for patients (pts) with advanced pancreatic cancer (APC) treated with anti-EGFR drugs have not yet been…”
Get full text

Decreased essential antioxidants and increased lipid hydroperoxides following high-dose radiochemotherapy by Clemens, M R, Ladner, C, Schmidt, H, Ehninger, G, Einsele, H, Bühler, E, Waller, H D, Gey, K F

“…The blood from 19 patients having bone marrow transplantation was examined for the essential antioxidants alpha-tocopherol and beta-carotene as well as lipid…”
Get more information

Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial by Gluz, Oleg, Kreipe, Hans Heinrich, Christgen, Matthias, Degenhardt, Tom, Kates, Ronald E., Liedtke, Cornelia, Shak, Steven, Clemens, Michael R., Salem, Marwa, Markmann, Susanne, Liedtke, Bernd, Aktas, Bahriye, Henschen, Stephan, Pollmanns, Anke, Krabisch, Petra, Uleer, Christoph, Augustin, Doris, Thomssen, Christoph, Nitz, Ulrike, Harbeck, Nadia

“…Abstract only 552 Background: Use of multi-gene real-time PCR (RT-PCR) based assays e.g. Recurrence Score (RS) and single markers (grade, uPA/PAI-1, ER/PR,…”
Get full text